Entero Healthcare Solutions Limited has informed the Exchange regarding Outcome of Board Meeting held on February 12, 2026

Revenue growth above 20%Profit growth above 25%Exceptional itemResults View source PDF Explain this filing

ENTERO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.9%Reaction day

₹1151.40

prior close

₹1159.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-1.5%+0.6% vs market

Retailing peers, median of 55sector · industry level-1.5%+0.6% vs sector

On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 0.6 pts more than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.3

10m

-1.2

15m

-0.9

30m

-1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.9-1.5+0.6-1.5+0.6

Next day

-4.2-2.2-2.0-2.1-2.1

-4.0-1.2-2.8-2.4-1.6

-4.1-0.9-3.2-2.7-1.4

-5.9-2.3-3.5-4.9-1.0

-5.9-2.5-3.4-5.9+0.0

-10.9-3.6-7.3-8.2-2.6

15d

-9.2-10.4+1.2-13.1+4.0

-12.3-11.3-1.0-15.4+3.2

+7.6-3.6+11.2-8.4+16.0

+2.7+3.9-1.2-7.9+10.6

UpDownMarket · Nifty Microcap 250Sector · Retailing peers, median of 55Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Entero Healthcare Solutions reported its Q3FY26 (quarter ended December 31, 2025) results. On a consolidated basis, revenue from operations rose about 25.6% year-on-year to Rs. 1,706.5 crore, with profit after tax of Rs. 33.9 crore (up 15% YoY). For the nine months, consolidated revenue grew 24.6% to Rs. 4,681.3 crore and PAT grew 32.5% to Rs. 100.7 crore. On a standalone basis, Q3 revenue was Rs. 106.7 crore and PAT was just Rs. 0.8 crore, weighed down by a one-time Rs. 4.5 crore exceptional charge relating to the New Labour Codes (consolidated impact Rs. 8.18 crore). The board also granted 5,000 fresh ESOPs under the existing 2023 plan at an exercise price of Rs. 804 per option, and cancelled the previously announced acquisitions of Khera Medisolutions and AV Medisolutions citing commercial reasons. Statutory auditors MSKA & Associates issued an unmodified review opinion on both standalone and consolidated results.

Likely market impact

Consolidated results show healthy double-digit revenue and profit growth, driven by acquisitions and scale, which should be viewed positively by investors. The New Labour Codes charge is a one-time, non-cash item and does not affect ongoing operations. The cancellation of two acquisitions removes a previously announced growth lever but suggests management is being cautious with capital deployment.